201 related articles for article (PubMed ID: 37961516)
21. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
22. Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer.
Yang YY; Lin SC; Lay JD; Cho CY; Jang TH; Ku HY; Yao CJ; Chuang SE
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834326
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass.
Aldonza MBD; Reyes RDD; Kim YS; Ku J; Barsallo AM; Hong JY; Lee SK; Ryu HS; Park Y; Cho JY; Kim Y
Sci Rep; 2021 Apr; 11(1):8016. PubMed ID: 33850249
[TBL] [Abstract][Full Text] [Related]
24. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism.
Huang JS; Cho CY; Hong CC; Yan MD; Hsieh MC; Lay JD; Lai GM; Cheng AL; Chuang SE
Free Radic Biol Med; 2013 Dec; 65():1246-1256. PubMed ID: 24064382
[TBL] [Abstract][Full Text] [Related]
26. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
Lotsberg ML; Wnuk-Lipinska K; Terry S; Tan TZ; Lu N; Trachsel-Moncho L; Røsland GV; Siraji MI; Hellesøy M; Rayford A; Jacobsen K; Ditzel HJ; Vintermyr OK; Bivona TG; Minna J; Brekken RA; Baguley B; Micklem D; Akslen LA; Gausdal G; Simonsen A; Thiery JP; Chouaib S; Lorens JB; Engelsen AST
J Thorac Oncol; 2020 Jun; 15(6):973-999. PubMed ID: 32018052
[TBL] [Abstract][Full Text] [Related]
27. AXL-Driven EMT State as a Targetable Conduit in Cancer.
Antony J; Huang RY
Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
[TBL] [Abstract][Full Text] [Related]
28. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network.
Wu X; Wang L; Pearson NA; Renuse S; Cheng R; Liang Y; Mun DG; Madugundu AK; Xu Y; Gill PS; Pandey A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439388
[TBL] [Abstract][Full Text] [Related]
30. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.
Jokela TA; Engelsen AST; Rybicka A; Pelissier Vatter FA; Garbe JC; Miyano M; Tiron C; Ferariu D; Akslen LA; Stampfer MR; Lorens JB; LaBarge MA
Front Cell Dev Biol; 2018; 6():41. PubMed ID: 29719832
[TBL] [Abstract][Full Text] [Related]
31. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
32. Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.
Ying X; Chen J; Huang X; Huang P; Yan S
Exp Ther Med; 2017 Jul; 14(1):785-790. PubMed ID: 28673000
[TBL] [Abstract][Full Text] [Related]
33. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
34. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
[TBL] [Abstract][Full Text] [Related]
35. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
36. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract][Full Text] [Related]
37. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
38. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Wilson C; Ye X; Pham T; Lin E; Chan S; McNamara E; Neve RM; Belmont L; Koeppen H; Yauch RL; Ashkenazi A; Settleman J
Cancer Res; 2014 Oct; 74(20):5878-90. PubMed ID: 25125659
[TBL] [Abstract][Full Text] [Related]
39. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.
Jimbo T; Hatanaka M; Komatsu T; Taira T; Kumazawa K; Maeda N; Suzuki T; Ota M; Haginoya N; Isoyama T; Fujiwara K
Oncotarget; 2019 Aug; 10(50):5152-5167. PubMed ID: 31497246
[TBL] [Abstract][Full Text] [Related]
40. The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma.
Cichoń MA; Szentpetery Z; Caley MP; Papadakis ES; Mackenzie IC; Brennan CH; O'Toole EA
Oncogene; 2014 Aug; 33(32):4185-92. PubMed ID: 24056961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
